DDInter1042 DDInter593
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Doxepin {u} (Compound) resembles {v} (Compound) Thiothixene
Doxepin {u} (Compound) resembles {v} (Compound) Imipramine
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Cyclobenzaprine
Doxepin {u} (Compound) binds {v} (Gene) HTR2A
Doxepin {u} (Compound) upregulates {v} (Gene) MCOLN1
Doxepin {u} (Compound) palliates {v} (Disease) atopic dermatitis
Doxepin {u} (Compound) downregulates {v} (Gene) FAM69A
Doxepin {u} (Compound) causes {v} (Side Effect) Elevated mood
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Doxepin (Compound) resembles Thiothixene (Compound)
Doxepin (Compound) resembles Imipramine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Doxepin (Compound) binds HTR2A (Gene)
Doxepin (Compound) upregulates MCOLN1 (Gene)
Doxepin (Compound) palliates atopic dermatitis (Disease)
Doxepin (Compound) downregulates FAM69A (Gene)
Doxepin (Compound) causes Elevated mood (Side Effect)